Adult T-cell leukemia/lymphoma is a rare malignancy associated with the human retrovirus human T-cell lymphotropic virus type 1. It is characterized by the proliferation of highly pleomorphic lymphocytes. Involvement of peripheral blood, bone marrow, lymph nodes, spleen, and extranodal sites such as skin, liver, gastrointestinal tract, and central nervous system can occur. There are four distinct clinical variants, and the prognosis and clinical course range from highly aggressive to a more protracted course depending on the subtype. We describe a man with de novo adult T-cell leukemia/lymphoma and discuss the unique clinical, morphologic, immunophenotypic, and molecular features of this entity.
A dult T-cell leukemia/lymphoma (ATLL) is an uncommon lymphocytic malignancy associated with human T-cell lymphotropic virus type 1 (HTLV-1). Th is disorder is endemic in several regions of the world where HTLV-1 is prevalent, in particular southwestern Japan, the Caribbean basin, and parts of central Africa (1) . Th e proliferation of highly pleomorphic lymphocytes with distinctive clinical, morphologic, and immunophenotypic features is characteristic (2) . Th e diversity in clinical features and prognosis of this disease has led to its classifi cation into four subtypes-acute, lymphomatous, chronic, and smoldering-which are defi ned by organ involvement, lactate dehydrogenase (LDH) levels, and calcium values (3). We report a case of de novo ATLL.
CASE PRESENTATION
A previously healthy 59-year-old Nigerian man presented with a 2-week history of a rapidly enlarging right-sided neck mass associated with dysphagia, odynophagia, and right neck pain. He had no weight loss, night sweats, or rash. Examination revealed a 10 × 6 cm fi rm conglomerate nodal mass in the right anterior cervical chain. Enlarged right supraclavicular lymph nodes, some enlarged left anterior cervical lymph nodes (1 × 1 cm), and right axillary adenopathy (3 × 2.5 cm) were also noted. A computed tomography (CT) scan of the neck revealed a 3.5 × 2.9 cm right palatine tonsillar mass with associated narrowing of the supraglottic larynx and oropharynx. Th e conglomerate nodal mass in the right side of the neck measured 10 cm in caudal dimension. Th ere was obliteration of the right internal jugular vein and encasement of the right internal carotid artery. Further staging with CT of the chest, abdomen, and pelvis revealed massive subpectoral and right axillary adenopathy, with the largest subpectoral node measuring 4.8 × 2.7 cm. Several additional mesenteric nodes were noted, the largest of which measured 3.1 × 1.7 cm. Th ere was splenomegaly of 12 cm. No bony lesions were seen on CT scan, and there was no evidence of hypercalcemia on presentation.
Notable laboratory values upon presentation included a white blood cell count of 20,000 K/μL, hemoglobin of 13.8 g/dL, and platelets of 204,000 K/μL. His LDH was 413 U/L (normal range, 0-250 U/L), and uric acid was 6.1 mg/dL. Results of an HIV test were negative. Review of the peripheral smear revealed numerous small-to medium-sized mononuclear cells with scant cytoplasm and convoluted nuclei, many of which had polylobated forms (Figure) . Bone marrow aspirate also revealed many of the same mononuclear cells seen on the peripheral smear. Core biopsy and immunohistochemical stains showed a 60% cellular marrow with a small population of aberrant T cells with loss of CD7. Flow cytometry on the bone marrow revealed a 14% aberrant Tcell population expressing CD2, CD3 (dim), CD4, CD5, CD25, CD45, CD52, and CD123 (partial). Th ese cells were negative for CD7 and CD8. Flow cytometry of peripheral blood revealed a 51% population of identical aberrant T cells. HTLV-1 antibody testing was positive by enzyme-linked immunosorbent assay and Western blot, confi rming a diagnosis of ATLL, aggressive subtype.
Chemotherapy with cyclophosphamide, prednisone, doxorubicin, and vincristine (CHOP) in conjunction with zidovudine and interferon alpha was promptly initiated. After one cycle of chemotherapy, there was marked decline in the size of his adenopathy and corresponding improvement in his dysphagia, odynophagia, and neck pain. His course was complicated by Strongyloides stercoralis in the stool, which was treated with ivermectin. He also had neutropenic fever due to Clostridium diffi cile colitis, which resolved with oral vancomycin. A positron emission tomography (PET) scan performed after his third cycle of chemotherapy revealed no evidence of residual lymphoma, and allogeneic stem cell transplant was planned. He completed six cycles of CHOP chemotherapy in conjunction with interferon and zidovudine, but unfortunately there was evidence of diff use osseous relapse on PET scan performed for restaging purposes prior to bone marrow transplant. Th is relapse was associated with bone pain and marked hypercalcemia, which was refractory to bisphosphonate therapy. Since his malignant T cells expressed CD52, second-line therapy with alemtuzumab was attempted, but he did not tolerate this therapy well and did not have a discernible clinical response. He was eventually transitioned to hospice and died shortly thereafter. DISCUSSION ATLL, a rare hematological malignancy, was fi rst described in Japan in 1977 as a distinct, progressive T-cell leukemia with a peculiar morphology. Due to the clustering of the disease in the southwestern portion of Japan, a viral etiology was suspected (2) . In the early 1980s, HTLV-1, the fi rst human retrovirus discovered, was isolated from leukemic cells from a patient with ATLL. Th is fi nding of an association between HTLV-1 and ATLL led to the virus's inclusion among human carcinogenic pathogens (4) . Later, in the mid to late 1980s, HTLV-1 was found to be associated with other, primarily infl ammatory, diseases including tropical spastic paraparesis, HTLV-1-associated myelopathy, HTLV-1 uveitis, and infective dermatitis (5) . Around the same time, other endemic areas for the virus and its associated diseases were found in addition to southwestern Japan, including several Caribbean islands, tropical Africa, South America, the Middle East, and northern Oceania (6) .
Approximately 20 million people worldwide are estimated to be infected with HTLV-1, and about 90% remain asymptomatic carriers throughout their lives. Th e cumulative risk of ATLL development among HTLV-1 carriers is estimated to be 2.5% to 5% over the course of a 70-year life span (7). Aff ected individuals are usually exposed to the virus early in life. Viral transmission predominantly occurs through breast milk, sexual intercourse, and exposure to peripheral blood and blood products (8) . Th e disease has a long latency, and thus ATLL occurs only in adults with onset ages ranging from 20 to 80, with an average age of 58 years. Males are more commonly aff ected, with a male to female ratio of 1.5 to 1 (9) .
Although HTLV-1 infection alone is not suffi cient in and of itself to result in neoplastic transformation, the virus does express a few genes demonstrated to aid in oncogenesis (1). In HTLV-1-infected lymphocytes, the p40 tax viral protein has been shown to lead to transcriptional activation of many genes inducing proliferation and inhibiting apoptosis in vivo. Another gene recently described, the HTLV-1 basic leucine zipper factor (HBZ), which is uniformly expressed in ATLL cells, seems to have a more important role in cellular transformation and leukemogenesis than does p40 tax. HBZ transcription appears to be correlated with provirus load and also with the severity of disease (5). Nevertheless, additional undefi ned genetic alterations over time in addition to these appear to be required to result in malignancy.
Once malignant transformation does occur, patients with ATLL show a variety of clinical manifestations due to various complications of organ involvement by leukemic cells, opportunistic infections, and/or hypercalcemia. Th ese three factors often contribute to the extremely high mortality of the disease (1) . Most patients present with widespread lymph node involvement as well as involvement of peripheral blood. Th e distribution of the disease is usually systemic, involving the spleen, extranodal sites including the skin and liver, and less common sites such as the lung, gastrointestinal tract, and central nervous system (10) . Th e number of circulating neoplastic cells does not correlate with the degree of bone marrow involvement, suggesting that circulating cells are recruited from other organs such as the skin. In fact, the skin is the most frequent extralymphatic site, with involvement in more than 50% of cases. Large nodules, plaques, ulcers, and erythrodermas are observed (11) . Immune suppression is common at presentation and during the course of disease progression. In a nationwide study in Japan, approximately 26% of 854 patients with ATLL had active infections at diagnosis. Th e infections were bacterial in 43%, fungal in 31%, protozoal in 18%, and viral in 8% of patients (12) . Th e diagnosis of ATLL requires the detection of characteristic cells in peripheral blood or tissue samples. Typical ATLL cells have convoluted nuclei with homogeneous and condensed chromatin, small or absent nucleoli, and agranular, basophilic cytoplasm. In the peripheral blood, the polylobated appearance of neoplastic cells has led to the term "fl ower cells," which are considered characteristic of ATLL (13) . ATLL cells in the skin and lymph node can vary in size from small to large, with forms including pleomorphic to anaplastic to Hodgkin-like with no specifi c histological pattern of involvement. Th e diff erential diagnosis includes Sézary syndrome, other peripheral T-cell lymphomas, and Hodgkin lymphoma, and establishing the true diagnosis can at times be diffi cult without demonstration of the presence of HTLV-1 (1).
After the diagnosis of ATLL has been established, determination of its subtype-which refl ects prognostic factors, clinical features, and the natural history of the disease based on the presence of organ involvement, leukemic manifestation, and values for LDH and calcium-is necessary for the selection of appropriate treatment. Th e four subtypes have been identifi ed as acute, lymphomatous, chronic, and smoldering ATLL (3) . Th e acute variant is the most common and is characterized by a leukemic phase, often with a markedly elevated white blood cell count, skin rash, and generalized lymphadenopathy. Th is systemic disease is accompanied by hepatosplenomegaly, constitutional symptoms, and elevated LDH. Hypercalcemia, with or without lytic bone lesions, occurs in 50% of patients with the acute variant. Parathyroid hormone-related protein or receptor activator of nuclear factor kappa B ligand (RANKL) produced by ATLL cells is considered the main cause for hypercalcemia. Many patients with the acute variant also have an associated T-cell immunodefi ciency, which frequently leads to opportunistic infections such as Pneumocystis jirovecii pneumonia and strongyloidiasis, the latter of which was present in our patient (14) . Th e lymphomatous variant is characterized by prominent lymphadenopathy, which is similar to the acute form but diff ers in that there is no peripheral blood involvement. Most patients present with advanced stage disease, although hypercalcemia is seen less often, in about 17% of cases.
In the less aggressive chronic and smoldering forms, symptoms are nonspecifi c and there is no tumor mass or lymphadenopathy. While an absolute lymphocytosis may be present in the chronic form, atypical lymphocytes are not numerous in the peripheral blood. Th e smoldering variant diff ers from the chronic variant in that the smoldering type is associated with a normal white blood cell count but with >5% circulating neoplastic cells (3) . Mild lymphadenopathy and hepatosplenomegaly may be present in the chronic form, but these manifestations are not present in the smoldering form. Hypercalcemia does not occur in either the chronic or smoldering subtypes. Cutaneous lesions can be seen in all four subtypes. Progression from the chronic or smoldering to the acute variant occurs in 25% of the cases, but usually after a long duration (1) . Th e survival rate varies depending on the subtype, with 4 to 6 months for the acute type, 9 to 10 months for the lymphomatous type, 17 to 24 months for the chronic type, and 34 months to >5 years for the smoldering type (14) .
Immunophenotypically, tumor cells characteristically express pan T-cell antigens CD2, CD3, and CD5 but usually lack CD7. Prototypical ATLL cells have a CD4 + , CD8 -mature helper T-cell phenotype, although a few cases are CD4 -, CD8 + or double positive for CD4 and CD8. CD25 is strongly expressed in nearly all cases, and malignant cells frequently also express the chemokine receptors CCR4 and FOXP3, features of regulatory T cells (15) . Th e large transformed cells may be positive for CD30, but anaplastic lymphoma kinase and cytotoxic molecules are negative, which helps to distinguish this entity from anaplastic large cell lymphoma (16) . Although cytogenetic studies do not show specifi c recurrent abnormalities, almost all ATLL cases have a high degree of numerical and structural chromosome abnormalities, and molecular studies always demonstrate T-cell receptor genes to be clonally rearranged (17) . Neoplastic cells show monoclonal integration of HTLV-1, while clonal integration is not present in healthy carriers (18) .
ATLL can range from indolent to very aggressive, and treatment strategies are usually off ered to patients with acute, lymphomatous, and unfavorable chronic variants while patients with typical chronic and smoldering ATLL are observed initially. Although chemotherapy is warranted, ATLL has been shown to be resistant to most regimens, and enrollment in clinical trials is recommended if possible. Th e monoclonal antibody alemtuzumab (anti-CD52) has also shown some effi cacy, but responses are still transient and further disease progression is inevitable (19) . Although autologous hematopoietic cell transplantations do not appear to be of benefi t due to frequent early relapses, allogeneic cell transplants off er a potential graft-versus-leukemia eff ect and may be considered for patients with an available donor (20) .
